

Supplemental Table 3. Summary of AntiDrug Antibody Data Incidence by Route of Administration

Dose Route	IV^A	SC^B
ADA incidence^C	0/6 (0%)	0/11 (0%)
Overall ADA prevalence^D	0/6 (0%)	0/11 (0%)
Baseline positive subjects	0/6 (0%)	0/11 (0%)
Subjects with treatment-boosted ADA	0/6 (0%)	0/11 (0%)
Subjects with treatment-induced ADA	0/6 (0%)	0/11 (0%)

^A Excludes 3 subjects without supporting documentation.

^B Excludes 1 subject that did not have baseline ADA data prior to initiation of dosing.

^C Proportion of subjects found to have seroconverted or boosted their pre-existing ADA with N-803 treatment.

^D Proportion of subjects having drug-reactive antibodies at any point in time (including prior to any N-803 administration).